175 related articles for article (PubMed ID: 29732576)
1. Transfusions of least-incompatible blood with intravenous immunoglobulin plus steroids cover in two patients with rare antibody.
Win N; Needs M; Thornton N; Webster R; Chang C
Transfusion; 2018 Jul; 58(7):1626-1630. PubMed ID: 29732576
[TBL] [Abstract][Full Text] [Related]
2. Prevention of hemolytic transfusion reactions with intravenous immunoglobulin prophylaxis in U- patients with anti-U.
Win N; Almusawy M; Fitzgerald L; Hannah G; Bullock T
Transfusion; 2019 Jun; 59(6):1916-1920. PubMed ID: 30861151
[TBL] [Abstract][Full Text] [Related]
3. Prevention of potential delayed hemolytic transfusion reaction in two sickle cell patients using intravenous immunoglobulins and steroids before and after red blood cell exchange with antigen positive units and review literature.
Shold J; Dasgupta A; Ye Z
Transfus Apher Sci; 2024 Jun; 63(3):103920. PubMed ID: 38570214
[TBL] [Abstract][Full Text] [Related]
4. Treatment with intravenous immunoglobulin and steroids may correct severe anemia in hyperhemolytic transfusion reactions: case report and literature review.
Win N; Sinha S; Lee E; Mills W
Transfus Med Rev; 2010 Jan; 24(1):64-7. PubMed ID: 19962576
[TBL] [Abstract][Full Text] [Related]
5. Autoantibody formation after alloimmunization inducing bystander immune hemolysis.
Mota M; Bley C; Aravechia MG; Hamerschlak N; Sakashita A; Kutner JM; Castiho L
Immunohematology; 2009; 25(1):9-12. PubMed ID: 19856726
[TBL] [Abstract][Full Text] [Related]
6. Blood group A mothers are more likely to develop anemia during antenatal intravenous immunoglobulin treatment of fetal and neonatal alloimmune thrombocytopenia.
Lakkaraja M; Jin JC; Manotas KC; Vinograd CA; Ferd P; Gabor J; Wissert M; Berkowitz RL; McFarland JG; Bussel JB
Transfusion; 2016 Oct; 56(10):2449-2454. PubMed ID: 27611703
[TBL] [Abstract][Full Text] [Related]
7. Case report: exacerbation of hemolytic anemia requiring multiple incompatible RBC transfusions.
Svensson AM; Bushor S; Fung MK
Immunohematology; 2004; 20(3):177-83. PubMed ID: 15373649
[TBL] [Abstract][Full Text] [Related]
8. Hyperhemolytic transfusion reaction attributable to anti-Fy3 in a patient with sickle cell disease.
Reyes MA; Illoh OC
Immunohematology; 2008; 24(2):45-51. PubMed ID: 19852130
[TBL] [Abstract][Full Text] [Related]
9. Acute hemolytic transfusion reaction caused by anti-Yt
Raos M; Thornton N; Lukic M; Golubic Cepulic B
Immunohematology; 2021 Mar; 37(1):13-17. PubMed ID: 33962487
[TBL] [Abstract][Full Text] [Related]
10. Hyperhemolysis syndrome in sickle cell disease: case report (recurrent episode) and literature review.
Win N; New H; Lee E; de la Fuente J
Transfusion; 2008 Jun; 48(6):1231-8. PubMed ID: 18373500
[TBL] [Abstract][Full Text] [Related]
11. Maternal hemolysis after intravenous immunoglobulin treatment in fetal and neonatal alloimmune thrombocytopenia.
Rink BD; Gonik B; Chmait RH; O'Shaughnessy R
Obstet Gynecol; 2013 Feb; 121(2 Pt 2 Suppl 1):471-3. PubMed ID: 23344412
[TBL] [Abstract][Full Text] [Related]
12. Acute and delayed hemolytic transfusion reactions secondary to HLA alloimmunization.
Benson K; Agosti SJ; Latoni-Benedetti GE; Leparc GF
Transfusion; 2003 Jun; 43(6):753-7. PubMed ID: 12757526
[TBL] [Abstract][Full Text] [Related]
13. Hyperhemolysis syndrome in anemia of chronic disease.
Darabi K; Dzik S
Transfusion; 2005 Dec; 45(12):1930-3. PubMed ID: 16371046
[TBL] [Abstract][Full Text] [Related]
14. Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility.
Mielke O; Fontana S; Goranova-Marinova V; Shebl A; Spycher MO; Wymann S; Durn BL; Lawo JP; Hubsch A; Salama A
Transfusion; 2017 Nov; 57(11):2629-2638. PubMed ID: 28840942
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of recurrent hyperhemolysis syndrome with immunosuppression and plasma-to-red blood cell exchange transfusion.
Uhlmann EJ; Shenoy S; Goodnough LT
Transfusion; 2014 Feb; 54(2):384-8. PubMed ID: 23692505
[TBL] [Abstract][Full Text] [Related]
16. High-dose intravenous immunoglobulin in non-ABO transfusion incompatibility.
Kohan AI; Niborski RC; Rey JA; Amerise G; Vázquez MI; Zani N; Calahonra R; Binaghi A; Sánchez Avalos J
Vox Sang; 1994; 67(2):195-8. PubMed ID: 7801611
[TBL] [Abstract][Full Text] [Related]
17. Post-transfusion hyperhaemolysis in a patient with sickle cell disease: use of steroids and intravenous immunoglobulin to prevent further red cell destruction.
Cullis JO; Win N; Dudley JM; Kaye T
Vox Sang; 1995; 69(4):355-7. PubMed ID: 8751307
[TBL] [Abstract][Full Text] [Related]
18. Hyperhemolytic transfusion reaction in sickle cell disease.
Win N; Doughty H; Telfer P; Wild BJ; Pearson TC
Transfusion; 2001 Mar; 41(3):323-8. PubMed ID: 11274584
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of anti-Jra: report of two cases and review of the literature.
Kwon MY; Su L; Arndt PA; Garratty G; Blackall DP
Transfusion; 2004 Feb; 44(2):197-201. PubMed ID: 14962310
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease.
Luban NL; Wong EC; Henrich Lobo R; Pary P; Duke S
Transfusion; 2015 Jul; 55 Suppl 2():S90-4. PubMed ID: 26174904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
